US Weighs Farmer Bailout as China Retaliation Threatens Exports
Agriculture Secretary Brooke Rollins said the administration is considering plans to offer assistance to farmers amid worries that the US-China trade war will have a disastrous effect on American agricultural producers.
China announced plans to increase tariffs on all American goods to 84% after President Donald Trump raised duties on Chinese imports to 104%. During a smaller trade fight with Beijing during Trump's first term, his administration used the Commodity Credit Corporation to offer $28 billion to bail out US farmers. The government-owned and operated entity was created to boost farm income and prices.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & SullivanWebsite: PR@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
32 minutes ago
- Yahoo
Trump's ‘Big Beautiful Bill' Would Slash Medicaid & SNAP: 3 Moves Retirees Should Make Now
President Donald Trump's 'one big beautiful bill' has passed in the House and is now awaiting Senate approval. If passed, Trump's signature bill would extend the tax cuts granted by the 2017 Tax Cuts and Jobs Act and add additional tax cuts. While this might be welcome news to many, the bill also includes changes to Medicaid and the Supplemental Nutrition Assistance Program (SNAP) that could threaten seniors' access to these programs. Find Out: Read Next: 'The 'one big beautiful bill' passed by the House of Representatives, if it were passed into law today, would cut Medicaid and SNAP by a combined $1 trillion,' said Chris Orestis, president of Retirement Genius. 'In addition, because of the increase to federal debt of as much as $5 trillion, the bill would trigger an automatic reduction in Medicare funding of $500 billion,' he continued. 'This would represent the largest cut to social services and health insurance for the poor, disabled, children and the elderly in U.S. history.' Here's a look at the changes retirees can make now to secure care and avoid benefit disruptions if the bill were to pass. Before changes go into effect, check with your healthcare providers to ensure there won't be any interruption to your care if there are cuts to Medicaid. 'Check with your healthcare provider to see if they might cut back on services or cease accepting Medicaid-funded patients, and contact any nursing home where you or a loved one may reside to find out if they will be reducing the number of patients they can support — or even [if they are] possibly planning to close,' Orestis said. Knowing this ahead of time will allow you to find alternative care providers before it's too late. Learn More: If you are reliant on SNAP, start searching for alternatives that may be able to provide food assistance in the event your benefits are reduced or cut. 'Make sure you know where there are local support services through community or faith-based organizations to replace lost access through SNAP,' Orestis said. Many retirees plan to 'spend down' their savings so that they qualify for Medicaid to pay for their long-term care. However, this may no longer be a viable option. 'If you are considering going onto Medicaid for long-term care and are preparing to engage the 'spend down' process to impoverish yourself and get below the poverty level to qualify, you may want to reconsider that strategy, and instead look to leverage private pay resources to pay for your care,' Orestis said. 'If you are on Medicaid, you will primarily be reliant on nursing homes for your care, and their ability to withstand these cuts will be very challenging and up in the air,' he continued. 'If you are private pay, you are in control and can decide where and when you will receive care, such as at home or an assisted living community not funded by Medicaid.' Strategies to stay private pay for long-term care would include long-term care insurance, annuities, a life insurance settlement, a reverse mortgage or VA benefits. Editor's note on political coverage: GOBankingRates is nonpartisan and strives to cover all aspects of the economy objectively and present balanced reports on politically focused finance stories. You can find more coverage of this topic on More From GOBankingRates Clever Ways To Save Money That Actually Work in 2025 This article originally appeared on Trump's 'Big Beautiful Bill' Would Slash Medicaid & SNAP: 3 Moves Retirees Should Make Now
Hamilton Spectator
38 minutes ago
- Hamilton Spectator
New crime novels feature a locked-room mystery, a Scarborough stabbing and a Jan. 6 insurrectionist
It's a weird time in American politics, which means it's a perfect time for Florida novelist Carl Hiaasen to plumb the satirical depths of corruption and malfeasance in his home state. His last novel, 2020's 'Squeeze Me,' suffered from a subplot that attempted to satirize the once-and-current occupant of the White House, a Falstaffian spray-tanned figure so outrageous as to be almost impervious to satire. For 'Fever Beach,' Hiaasen wisely steers clear of POTUS and his inept administration, preferring instead to focus on wanton corruption at a lower level. 'Fever Beach,' by Carl Hiaasen, Alfred A. Knopf, $34.99. The new novel begins with a meet-cute on an airplane between Twilly Spree and Viva Morales. Twilly is a stock Hiaasen character: an independently wealthy Florida do-gooder who spends his time making life miserable for folks who litter, antagonize the local wildlife or otherwise cause environmental or social havoc. Viva's job is administering the foundation of a couple of rich right-wing octogenarians whose fundraising operates as a money-laundering front to finance the campaign of far-right (and profoundly stupid) congressman Clure Boyette, in hot water with his obstreperous father over a scandal involving an underage prostitute named Galaxy. Add in Viva's landlord — a Jan. 6 insurrectionist named Dale Figgo who heads the Strokers for Freedom (a white nationalist militia whose name is a rebuke to the Proud Boys' insistence on refraining from masturbation) — and his cohort, the violent and reckless Jonas Onus, and you have all the ingredients for a classic Hiaasen caper. Twenty years ago, German-born author Leonie Swann debuted one of the most delightful detective teams in genre history: a flock of sheep on the trail of the person responsible for killing their shepherd with a spade through the chest. After a two-decade absence, Miss Maple, Othello, Mopple the Whale, and the other woolly sleuths are back on the case, this time on behalf of their new herder, Rebecca, the daughter of the early book's victim. 'Big Bad Wool,' by Leonie Swann, Soho Crime, $38.95. Rebecca, her intrusive Mum, and the sheep are overwintering in the lee of a French chateau where there are rumours of a marauding Garou — a werewolf — that is responsible for mutilating deer in the nearby woods. Among other strange occurrences, Rebecca's red clothing is found torn to pieces and some sheep go missing — and soon enough there's a dead human for the flock, in the uncomfortable company of a group of local goats, to deal with. 'Big Bad Wool' is a charming romp, whose pleasure comes largely from the ironic distance between the sheep's understanding of the world and that of the people who surround them. ('The humans in the stories did plenty of ridiculous things. Spring cleaning, revenge and diets.') Their enthusiasm and excitement results in prose that is a bit too reliant on exclamation points, and some of the more heavy-handed puns (like the sheep's insistence on 'woolpower') seem forced, but this is nevertheless a fun variation on the traditional country cosy. Romance novelist Uzma Jalaluddin takes a turn into mystery with this new book about amateur sleuth Kausar Khan. A widow in her late 50s, Kausar returns to Toronto from North Bay to help her daughter, Sana, who has been accused of stabbing her landlord to death in her Scarborough mall boutique. The police — including Sana's old flame, Ilyas — are convinced Sana is the prime suspect, but Kausar is determined to prove her daughter innocent. 'Detective Aunty,' by Uzma Jalaluddin, HarperCollins, $25.99. Her investigation involves a couple of competing developers, both of whom want to purchase the land on which the mall stands, along with members of the dead man's family and fellow shopkeepers. On the domestic front, Kausar finds herself concerned with Sana's deteriorating marriage to her husband, Hamza, and her teenage granddaughter's sullenness and mysterious nighttime disappearances. Jalaluddin does a good job integrating the various elements of her plot, and the familial relationships are nicely calibrated. The momentum is impeded, however, by a preponderance of clichés ('Playing devil's advocate, Kausar asked …'; 'Kausar's blood ran cold') and a tendency to hold the reader's hand by defining every easily Googleable Urdu word or greeting too programmatically. More attention to the writing on the line level would have helped move this one along. Yukito Ayatsuji's clever postmodern locked-room mystery was first published in Japanese in 2009; it appears for the first time in English translation, which is good news for genre fans. 'The Labyrinth House Murders,' by Yukito Ayatsuji, Pushkin Vertigo, $24.95. Ayatsuji's narrative is framed by Shimada, a mystery aficionado, who is presented with a novelization about murders that took place at the home of famed mystery writer Miyagaki Yotaro, found dead by his own hand soon after the manuscript opens. Miyagaki has left a bizarre challenge for the writers gathered at his Byzantine Labyrinth House: each must write a story featuring a murder, and the victim must be the writer him- or herself. The winning author, as adjudicated by a group of critics also convened at Labyrinth House, will inherit Miyagaki's sizable fortune. As the writers compete for the reward, bodies start falling in real life and Ayatsuji has a grand time playing metafictional games with his readers, challenging them to figure out who the culprit is in the context of a story that owes more than a small debt to Agatha Christie's 'And Then There Were None.' But Ayatsuji does Christie one better; it is only once the afterword, which closes the framed narrative, has unfolded that the reader fully understands how cleverly the author has conceived his multi-layered fictional trap.
